This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

n-3 Fatty Acid Infusion and Type 2 Diabetes

This study has been completed.
Norwegian University of Science and Technology
Norwegian Foundation for Health and Rehabilitation
Novo Nordisk A/S
Norwegian Diabetes Association
Information provided by (Responsible Party):
St. Olavs Hospital Identifier:
First received: January 26, 2009
Last updated: November 3, 2011
Last verified: November 2011
The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids. Furthermore other effects on intermediary metabolism are tested for.

Condition Intervention
Type 2 Diabetes Dietary Supplement: Intralipid +/- Omegaven

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by St. Olavs Hospital:

Primary Outcome Measures:
  • insulin sensitivity [ Time Frame: 4 hours ]

Secondary Outcome Measures:
  • n-3 fatty acid distribution [ Time Frame: 4 hours ]
  • insulin secretion [ Time Frame: 4 hours ]
  • energy metabolism [ Time Frame: 4 hours ]
  • oxidative stress [ Time Frame: 4 hours ]

Enrollment: 11
Study Start Date: January 2004
Study Completion Date: October 2008
Primary Completion Date: May 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intralipid with/without Omegaven
Lipid infusion with/without marine n-3 fatty acids
Dietary Supplement: Intralipid +/- Omegaven

Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.

Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.

Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).

Other Names:
  • Fresenius Kabi, ATC main group B05B A 02
  • Intralipid Vnr 42 79 55
  • Omegaven Vnr 55 25 54

Detailed Description:
Evidence indicates that n-3 fatty acids exert several beneficial effects. However, the effects of marine n-3 fatty acids on intermediary metabolism have not been completely elucidated. In a previous study of a high intake of marine n-3 fatty acids during 9 wk we demonstrated reduced insulin sensitivity and altered proportion of carbohydrate vs. fat oxidation in subjects with type 2 diabetes. These results question the use of high doses of n-3 supplements in type 2 diabetes. It is not known to what extent such effects in type 2 diabetes can be reproduced by intravenous administration of n-3 fatty acids and/or whether short term intravenous administration has other effects.

Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes defined by clinical criteria and by absence of antibodies to glutamic acid decarboxylase.
  • HbA1c 5,5 - 8,5 %
  • Blood pressure ≤ 170 mm Hg systolic and/or ≤ 105 mm Hg diastolic

Exclusion Criteria:

  • insulin treatment
  • hypertriglyceridemia (> 2,1 mmol/l TG)
  • proliferative retinopathy, renal insufficiency (Se-Creatinine > 150 μmol/l)
  • alcoholism, congestive heart failure or other serious diseases affecting the possibility of the subject to participate
  • supplement with fish oil or marine n-3 fatty acids during the last 6 months before baseline
  • Dicumarol treatment
  • allergy to soya, fish or egg
  • pregnancy or lactation
  • smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00829569

Department of Medicine, Division of Endocrinology, St. Olavs Hospital
Trondheim, Norway, N-7006
Sponsors and Collaborators
St. Olavs Hospital
Norwegian University of Science and Technology
Norwegian Foundation for Health and Rehabilitation
Novo Nordisk A/S
Norwegian Diabetes Association
Principal Investigator: Valdemar Grill, M.D. St. Olavs Hospital, NTNU
  More Information

Responsible Party: St. Olavs Hospital Identifier: NCT00829569     History of Changes
Other Study ID Numbers: 4.2003.169
03-14463 ( Other Identifier: SLV )
15759 ( Other Identifier: The Data Inspectorate )
03/05008 ( Other Identifier: Biobank )
Study First Received: January 26, 2009
Last Updated: November 3, 2011

Keywords provided by St. Olavs Hospital:
fish oil
hyperinsulinemic isoglycemic clamps
C-peptide glucagon test
indirect calorimetry

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Soybean oil, phospholipid emulsion
Fat Emulsions, Intravenous
Parenteral Nutrition Solutions
Pharmaceutical Solutions processed this record on August 18, 2017